WILLIAM ONDO: Open Payments
NPI 1851471437 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$217,109 in 308 payments from 22 companies in 2025. Trend: 2023 $261,808 · 2024 $209,609 · 2025 $217,109
Speaker / faculty: $128,165Consulting: $34,815Honoraria: $28,752Travel & lodging: $17,314Food & beverage: $6,615Education: $1,448
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 42 | $57,972 |
| MDD US Operations, LLC | 56 | $38,378 |
| ACADIA Pharmaceuticals Inc | 43 | $37,421 |
| Neurocrine BioSciences, Inc. | 45 | $30,896 |
| ABBVIE INC. | 55 | $21,767 |
| Merz Pharmaceuticals, LLC | 26 | $16,985 |
| Amneal Pharmaceuticals LLC | 12 | $7,641 |
| UCB SA | 2 | $2,240 |
| ORPHALAN INC | 1 | $1,800 |
| Ipsen Pharma SAS | 1 | $750 |
Products named: AUSTEDO XR, INGREZZA, NUPLAZID, INBRIJA, BOTOX, CREXONT, Gocovri, ACP-711.
Industry payments across TX — which companies pay providers there.
